000020.KS
Dongwha Pharm.Co.,Ltd
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 5,200.00
+0.78%Year over year
Reported trailing growth
- Revenue
- -15.5%
- EBITDA
- -77.6%
- EBIT
- +252.4%
- EPS
- +185.7%
- Free cash flow
- +96.4%
- Operating cash flow
- +1225.6%
Forward estimates
Based on analyst estimates
- Revenue
- -46.0%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +13.4%
- EBITDA
- -17.9%
- EBIT
- —
- Net income
- -24.7%
- EPS
- -24.8%
- Free cash flow
- +52.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026